We would like to introduce a fast and adaptive approach for treating serious diseases such as cancer by using our genetically engineered viruses and novel RNAi technology, which enables us to target the disease-specific pathways in a deep level.
Bringing together the brightest minds, we aim to build a strong and sturdy platform for new drug discovery.
Curigin has developed a novel viral oncolytic gene therapy that exclusively targets cancer cells that destroys them through infectious attack. By incorporating our novel RNAi technology, we “shut down” crucial cancer survival pathways, such as mTOR (mammalian target of rapamycin) and STAT3 (signal transducer and activator of transcription 3) among many others.
Our virus is modified to avoid infecting normal cells. This is done by binding to receptors that are highly expressed on cancer cells with a cancer specific promoter to initiate viral replication.
Another indirect result of our oncolytic therapy is the activation of the immune system, specifically T cells, by the release of virus, cytokines and antigens from dead cancer cells.